Regional brain distribution and binding of the muscarinic receptor agonist ci-979 studied by positron emission tomography in the monkey

Dementia and Geriatric Cognitive Disorders

Volumn 8, Issue 5, 1997, Pages 259-266

  Per, Hartvig ^a,c,d   Richard, Torstenson ^a,b   Peter, Bjurling ^a,c,d   Karl Johan, Fasth ^a,c,d   Bengt, Långström ^a,c,d   Agneta, Nordberg ^e  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b Hospital Pharmacy   (Sweden)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^d UPPSALA UNIVERSITY   (Sweden)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Brain; Cholinergic muscarinic receptor agonist; CI 979; Muscarinic receptors; Positron emission tomography; Rhesus monkey

Indexed keywords

ACETYLCHOLINE; CARBON 11; MUSCARINIC AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; BRAIN BLOOD FLOW; BRAIN TOMOGRAPHY; CORPUS STRIATUM; FEMALE; NONHUMAN; OCCIPITAL CORTEX; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR DENSITY; RHESUS MONKEY; TEMPORAL CORTEX;

EID: 0030792627     PISSN: 14208008     EISSN: 14219824     Source Type: Journal    
DOI: 10.1159/000106642     Document Type: Article

References (31)

1. Hardy JA, Adolfsson R, Alafuzof TI, Buchi G, Marcusson J, Nyberg P, Pcrdahl E, Wester P, Winblad B: Transmitter deficits in Alzheimer's disease, Neureichem Int 1985;7:545-563.
2. Perry EK: The cholinergic hypothesis: Ten years on, Br Med Bull 1986;42:63-69
3. Nordberg A: Neuroreceptor changes in Alzheimer's disease, Cercbrovasc Brain Metab Res 1992;4:303-328.
4. Giacobini E, Becker R (eds): Alzheimer disease: Therapeutic Strategies, Boston, Birkhäuser, 1994.
5. Scdman AJ, Bockbraader H, Schwarz RD: Prc-clinical and phase 1 clinical characterization of CI979/RU 35926, a novel muscarinic agonist for the treatment of Alzheimer's disease, Life Sci 1995;56:877-882.
6. Hoover TM: C1-979/RU 35926: A novel muscarinic agonist for the treatment of Alzheimer's disease; in Giacobini E, Becker R (cds): Alzheimer's Disease: Boston, Birkhäuser, 1994, pp 239-243.
7. Nordberg A: Clinical studies in Alzheimer patients with positron emission tomography, Be-hav Brain Res 1993;57:215-234.
8. Heiss WD, Kessler J, Szelies B, Herholz K: Long-term effects of phosphatidylscrinc, pyriti-nol and cognitive training in Alzheimer's disease: A neuropsychological, EEG, and PET investigation, Dementia 1994;5:88-89.
9. Nordberg A: Functional studies of new drugs for the treatment of Alzheimer's disease, Acta Neurol Scand 1996;93(suppl 165): 137-144.
10. Nordberg A, Lilja A, Lundqvist H, Hartvig P, Amberla K, Viitanen M, Warpman U, Johansson M, Hcllslröm-Lindahl E, Bjurhng P, Fasth KJ, Längström B, Winblad B: Tacrine restores cholinergic nicotinic receptors and glucose metabolism in Alzheimer patients as visualized by positron emission tomography, Ncurobiol Aging 1992:13:747-758.
11. Eriksson L, Holte S, Bohm C, Kesselberg M, Hovandcr B: Automated blood sampling systems for positron emission tomography, IEEE Trans Nucl Sei 1988:35:703-704.
12. Salmon E, Brooks DJ, Lccndcrs KL, Turton DR, Hume SP, Cremer JE, Jones T, Fracko-wiak RSJ: A 2-compartmcnt description and kinetic procedure for measuring regional cerebral C-l I (nomifensine uptake using positron emission tomography, J Cercb Blood Flow Mc-tab 1990;10:307-316.
13. lsF)fluoro-L-DOPA in Parkinsons' disease measured with positron emission tomography, Acta Neurol Scand 1990:81:24-30
14. L'0, I, Theory and error analysis, J Nucl Med 1983: 24:782-789.
15. l50, II, Implementation and validation, J Nucl Med 1983:24:790-798.
16. l?0 autoradiographical method and dynamic PET, J Nucl Med 1989:30:1069-1078.
17. Bonner TI: The molecular basis of muscarinic density, Trends Neurosci 1989:12:148-151
18. Svensson A-L, Alafuzoff I, Nordberg A: Characterization of muscarinic receptor subtypes in Alzheimer and control brain cortices by selective muscarinic agonists, Brain Res 1992: 596:142-148.
19. Cowburn RF, Fowler CJ, O'Neill C: Ncuro-Iransmitters, signal transduction and second messenger in Alzheimer's disease, Acta Neurol Scand 1996:93(suppl 165):25-32.
20. Smith CJ, Perry EK, Perry KH, Fairnbairn AF, Birdsall NJM: Guanine nucleotide modulation of muscarinic cholinergic receptor binding in postmortem human brain: A preliminary siudy in Alzheimer's disease, Neurosci Lett 1986:82: 227-232.
21. Flynn DD, Weinstein DA, Mash DC: Loss of high-affinity agonist binding to MI muscarinic receptors in Alzheimer's disease: Implications for the failure of cholinergic replacement therapies, Ann Neurol 1991:29:256-262.
22. Warpman U, Alafuzoff I, Nordberg I: Coupling of muscarinic receptors to G-proteins in postmortem human brain: Alterations in Alzheimer's disease, Neurosci Lett 1993:150:39-43.
23. Cowbum RF, Wichager B, Ravid R, Winblad B: Acetylcholine muscarinic M2 receptor stimulated [35S]GTPgS binding shows regional selective changes in Alzheimer's disease postmortem brain, Neurodegencration 1996:5:19-26.
24. Fisher A, Hcldman E, Gurwitz D, Haring R, Karton Y, Mesulam H, Pittel Z, Marciano D, Brandcis R, Sadot E, Barg Y, Pinkas-Karmar-ski R, Vogel Z, Ginsburg I, Treves A, Verchov-skv R, Kilmowskv S, Korcyzn AD: MI agonists for the treatment of Alzheimer's disease: Novel properties and clinical update, Ann NY Acad Sci 1996;777:189-196.
25. Bodick NC, DeLong AF, Bonatc PL, Gillespie T, Henry DP, Satterwhite JH, Lucas RA, Heaton J, Carter GV: Xanomclinc, a specific Ml-agonist: Early clinical studies; Giacobini E, Becker R (eds): Alzheimer's Disease: Therapeutic Strategies, Boston, Birkhauscr, 1994, pp 234-238.
26. MC-methyl]benztropine, Synapse 1990;5:213-223.
27. Frey KA, Koeppe RA, Mulholland GK, Jewett D, Hichwa R, Ehrenkaufer RLE, Carey JE, Wieland DM, Kuhl DE, Agranol TBW; In vivo muscarinic cholinergic receptor imaging in human brain with [' 'CJscopolamine and positron emission tomography, J Ccrcb Blood Flow Mc-tab 1992;12:147-154.
28. Mulholland GK, Otto CA, Jewett DM, Kil-boum MR, Koeppe RA, Sherman PS, Pctry NA, Carey JE, Atkinson ER, Archer S, Frey KA, Kuhl DE: Synthesis, rodent biodistribution, dosimetry, metabolism and monkey images of carbon-11-labelled (+)2-tropanyl bcnzilate: A central muscarinic receptor imaging agent, J Nucl Med 1992:33:423-430.
29. Varastct M, Brouillet E, Chavoix C, Prenant C, Crouzel C, Stulzaft O, Bottlandcr M, Crayla J, Mazierc B, Maziere M: In vivo visualization of central muscarinic receptors using CJ-quinu-clidinyl benzilate and positron emission tomography in baboons, Bur J Pharmacol 1992; 213:275-284.
30. nC]NMPB, a muscarinic acetylcholine receptor agonist, Nucl Med Biol 1995;22:13-17
31. nC]xanomeline and "Cjbutyl-thio-TZTP in monkey and man, Dementia 1996;7:187-195.